Deborah Mukherji· @dmukherji · X·· 2 天前评分70
正文 · 原文
Updated CAPItello-281 data at #ESMO26
In PTEN-deficient mHSPC, capivasertib + abiraterone improved median OS (57.4 vs 46.5 months; HR 0.82) and rPFS (35.5 vs 26.0 months).
Encouraging OS trend, but not statistically significant at this analysis #KarimFizazi @OncoAlert
288 浏览 · 5 赞 · 5 转发 · 0 回复
会议摘要
Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): Updated overall survival (OS) from CAPItello-281
https://esmocongress.esmo.org来源：Deborah Mukherji · x.com